Co-Authors
This is a "connection" page, showing publications co-authored by Kelvin To and Jonathan Ip.
Connection Strength
3.050
-
Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain. Clin Microbiol Infect. 2021 Sep; 27(9):1350.e1-1350.e5.
Score: 0.911
-
Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. Clin Infect Dis. 2021 11 02; 73(9):e2946-e2951.
Score: 0.244
-
The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. EBioMedicine. 2021 Sep; 71:103544.
Score: 0.241
-
Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination. Clin Infect Dis. 2021 Jul 26.
Score: 0.240
-
Unique Clusters of Severe Acute Respiratory Syndrome Coronavirus 2 Causing a Large Coronavirus Disease 2019 Outbreak in Hong Kong. Clin Infect Dis. 2021 07 01; 73(1):137-142.
Score: 0.238
-
Phylogenomic analysis of COVID-19 summer and winter outbreaks in Hong Kong: An observational study. Lancet Reg Health West Pac. 2021 May; 10:100130.
Score: 0.234
-
Evaluation of simple nucleic acid extraction methods for the detection of SARS-CoV-2 in nasopharyngeal and saliva specimens during global shortage of extraction kits. J Clin Virol. 2020 08; 129:104519.
Score: 0.222
-
Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole-genome sequencing. J Med Virol. 2020 11; 92(11):2725-2734.
Score: 0.222
-
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020 05; 20(5):565-574.
Score: 0.218
-
Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. Nat Commun. 2021 03 09; 12(1):1517.
Score: 0.058
-
Loss of orf3b in the circulating SARS-CoV-2 strains. Emerg Microbes Infect. 2020 Dec; 9(1):2685-2696.
Score: 0.057
-
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 05 30; 395(10238):1695-1704.
Score: 0.055
-
Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe. 2020 May; 1(1):e14-e23.
Score: 0.055
-
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 02 15; 395(10223):514-523.
Score: 0.054